Shenzhen Sciprogen Bio-pharmaceutical Co., Ltd.

Shenzhen Sciprogen Bio-pharmaceutical Co., Ltd. is a high-tech biopharmaceutical enterprise, a Sino-foreign joint venture, established in 1999 with a registered capital of 160 million yuan. It is located at No. 14 Yayuan Road, Bantian Street, Longgang District, Shenzhen, with a factory area of over 9,000 square meters and nearly 300 workers. It mainly produces recombinant human erythropoietin, low molecular weight heparin calcium, nadroparin calcium, etc. The company was certified as a "Shenzhen High-tech Enterprise" in 2007; has been certified as a national "High-tech Enterprise" since 2009; passed the new version of GMP certification in 2013; in 2014, "SEPO" was awarded the title of "Guangdong Famous Trademark"; in 2014, it was awarded the AAA Enterprise Credit Rating Certificate by the Ministry of Commerce; in 2014, it was awarded the honorary title of "Shenzhen Famous Brand"; in 2016, it was awarded "Excellent Enterprise" in the Guangdong Pharmaceutical Industry; in 2020, it passed the "Guangdong Specialized, Refined, Distinctive and Innovative SME" certification; in 2021, it passed the "Guangdong Engineering Technology Research Center" certification; in 2023, it passed the "Shenzhen Engineering Laboratory" certification. In 2014, the company merged with Shenyang Sunshine Pharmaceutical Co., Ltd., becoming a wholly-owned subsidiary of the Hong Kong-listed Sunshine Pharmaceutical (HK.01530). It is dedicated to research and development, production, sales, and services primarily in biopharmaceuticals, as well as in biochemical drugs and life health-related fields. The company holds a "Drug Production License", "Drug GMP Certificate", and multiple drug approval numbers and other qualification certificates. The company has a complete modern genetic engineering drug production plant, facilities, and advanced production technology and process equipment. At its establishment, it was designated by the Shenzhen Municipal Government as the "Shenzhen Bioengineering Industrialization Base". Currently, its main products in production include the biological product recombinant human erythropoietin (rhEPO) and its preparations, and biochemical drugs low molecular weight heparin and its preparations, etc.